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Abstract
Introduction A novel, red-shifted bioluminescence imaging (BLI) system called AkaBLI has been recently developed for 
cell tracking in preclinical models and to date, limited data is available on how it performs in relation to existing systems.
Purpose To systematically compare the performance of AkaBLI and the standard Firefly luciferase (FLuc) systems to moni-
tor the biodistribution and fate of cell therapies in rodents.
Methods Umbilical cord mesenchymal stromal cells (MSCs) were transduced to produce two genetically engineered popula-
tions, expressing either AkaLuc or the engineered FLuc luc2. The bioluminescence of  AkaLuc+ and  FLuc+ cells was assessed 
both in vitro (emission spectra, saturation kinetics and light emission per cell) and in vivo (substrate kinetics following 
intraperitoneal and subcutaneous administration and biodistribution of the cells up to day 7).
Results Introduction of the reporter genes has no effect on MSC phenotype. For BLI, the FLuc system is superior to AkaBLI 
in terms of (i) light output, producing a stronger signal after subcutaneous substrate delivery and more consistent signal 
kinetics when delivered intraperitoneally; (ii) absence of hepatic background; and (iii) safety, where the AkaLuc substrate 
was associated with a reaction in the skin of the mice in vivo.
Conclusion We conclude that there is no advantage in using the AkaBLI system to track the biodistribution of systemically 
administered cell-based regenerative medicine therapies in vivo.
Keywords Bioluminescence imaging · Reporter genes · Mesenchymal stromal cells · Cell therapies · Animal models
Introduction
Bioluminescence imaging (BLI) is a standard non-invasive 
technique that can be used to evaluate cell biodistribution, 
safety and viability longitudinally in small animals [1–4]. 
BLI is based on the emission of light during the oxidation 
of a substrate (luciferin) catalysed by a specialised enzyme 
(luciferase). Cells expressing a luciferase genetic reporter 
can then be easily detected by BLI in vivo following the 
administration of the relevant substrate. Firefly luciferase 
(FLuc) and the substrate D-Luciferin constitute one of the 
main BLI systems used in vivo in small animals [5–7]. When 
D-Luciferin is oxidised by FLuc, the wavelength of ~ 50% of 
the emitted photons is below 600 nm [5, 8] which results in 
them being strongly attenuated by mammalian tissues [9], 
reducing sensitivity.
Different approaches have been used to produce BLI sys-
tems with near-infrared light emission peaks [5, 10–14]. A 
recently developed novel BLI system consists of a luciferin 
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analogue, the Akalumine-HCl, and a mutated form of FLuc, 
called AkaLuc [15, 16]. This BLI system has a light emis-
sion peak around 650 nm and has been shown to provide 
a light output that is 52-fold stronger than that generated 
by FLuc when used in vivo [15]. This dramatic increase 
in sensitivity meant it was possible to detect signal from a 
single cell following intravenous injection [15]. All these 
characteristics make the AkaLuc/Akalumine-HCl (AkaBLI) 
system very promising for cell tracking. However, a rigorous 
comparison of the FLuc/D-luciferin and AkaBLI systems 
has not yet been undertaken, nor has AkaBLI been validated 
for applications in regenerative medicine.
Currently, there are over 3300 clinical trials active or in 
recruitment all over the world (clinicaltrials.gov) where mes-
enchymal stromal cells (MSCs) are being assessed for their 
therapeutic potential. Consequently, collecting adequate pre-
clinical data relating to the safety, biodistribution, and fate of 
these cells is of major interest, and can be achieved in small 
animals using BLI [17]. Here, we applied genetic engineer-
ing to produce two umbilical cord (UC-)MSCs populations, 
encoding either for the engineered FLuc luc2 or AkaLuc, 
and we compared these two populations both in vitro and 
in vivo, to identify which of the two BLI systems is the 




We obtained p3 human umbilical cord-derived mesenchymal 
stromal cells (UC-MSCs) from the National Health Service 
Blood and Transplant (NHSBT, UK), and we cultured them 
following standard mammalian tissue culture protocols. 
In short, the cells were grown in MEM-α containing Glu-
taMAX (Gibco) and supplemented with 10% foetal bovine 
serum (FBS; Sigma) and kept at 37 °C in a humidified incu-
bator, with 5%  CO2.
Generation of reporter cell lines
We transduced UC-MSCs with lentiviral vectors encod-
ing either the luc2 firefly luciferase (FLuc) or the AkaLuc 
reporter. The pHIV-Luc2-ZsGreen vector was a gift from 
Bryan Welm and Zena Werb (Addgene plasmid #39,196) 
and the pcDNA3-Venus-AkaLuc vector was a gift from 
Atsushi Miyawaki (Riken Plasmid #RDB15781) [15]. The 
pHIV-AkaLuc-ZsGreen vector was created by replacing the 
luc2 sequence with AkaLuc, generating two vectors that 
shared the same backbone, promoter (constitutive elonga-
tion factor 1-α, EF1α, promoter) and the ZsGreen fluores-
cent protein downstream of the bioluminescence reporter 
via an IRES linker, as described in Supplementary Fig. 1a. 
Lentiviral particles were produced using standard protocols 
[18] by co-transfection of HEK cells with the transfer vector 
(pHIV-Luc2-ZsGreen or pHIV-AkaLuc-ZsGreen), an enve-
lope plasmid (pMD2.G) and a packaging plasmid (psPAX2), 
concentration by ultracentrifugation and titration using HEK 
cells, based on ZsGreen expression.
We infected p5 UC-MSCs with a multiplicity of infection 
(MOI) of 5 in the presence of 20 μg/mL protamine sulphate 
(Sigma). We further employed a spinoculation protocol, 
where the plate containing the cells and the viral particles 
was centrifuged at 750 g for 1 h and then incubated at 37 °C 
for an extra hour, before a washing step with fresh medium 
[19]. The cells were then grown for another 7 days before 
they were sorted based on ZsGreen fluorescence, leading to 
two p6 UC-MSC populations that were 100% positive for 
either the FLuc or the AkaLuc. After expansion, we cryopre-
served the transduced cells at p7. In vitro experiments were 
carried out with cells at p8-9 and all in vivo bioluminescence 
experiments with cells at p8.
To determine marker expression via flow cytom-
etry, we detached the cells with Trypsin–EDTA (0.05% 
trypsin, 0.02% EDTA) and stained them with anti-CD44 
(APC, #130–113-893, Miltenyi Biotec), anti-CD45 
(APC, #130–113-676, Miltenyi Biotec), anti-CD73 
(APC, #130–097-945, Miltenyi Biotec), anti-CD90 (APC, 
#130–117-534, Miltenyi Biotec), anti-CD105 (APC, 
#130–099-125, Miltenyi Biotec), IgG1 mouse isotype 
(APC, #130–113-758, Miltenyi Biotec), or IgG2 mouse 
isotype (APC, #130–113-831, Miltenyi Biotec) according 
to the manufacturer’s instructions. An extra vial of each cell 
population was used as unstained blank. We acquired the 
data with a FACScalibur (BD Biosciences) and we analysed 
a minimum of  104 events for each marker.
Doubling time
From p7 to p12, the cells were counted and plated at 3 ×  103 
cells/cm2 at each passage, and the doubling time calculated 
using the following equation:
where Td is the doubling time,  Nt is the number of cells at 
time t and  N0 is the number of cells seeded, from which the 
number of doublings was calculated based on the time the 
cells had been in culture.
Morphological analysis
We seeded the cells at 3 ×  103 cells/cm2 into 8-well cham-
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Fig. 1  AkaLuc and FLuc transduced cells retain characteristics of 
untransduced UC-MSCs. a Schematic of the lentiviral vector used to 
generate MSCs expressing the reporters. The same vector backbone 
was used, and only the gene encoding for the luciferase was modi-
fied for expression of either FLuc or AkaLuc. Image produced using 
SnapGene software (from Insightful Science;  available at snapgene.
com). b Representative phase contrast and fluorescence images of 
untransduced, AkaLuc and FLuc expressing MSCs when fully conflu-
ent. ZsGreen expression can be observed in the green channel for the 
transduced cells. Scale bar = 200  μm. c Levels of transgene expres-
sion in  AkaLuc+ and  FLuc+ MSCs at different passages. ZsGreen 
expression was measured via flow cytometry at p7 and p12 and 
untransduced MSCs were used as a negative control. The levels of 
ZsGreen are equivalent for both populations at p7 and remain largely 
unchanged up to p12, with a slight reduction for AkaLuc cells. The 
mean fluorescence intensity (MFI) of FLuc population shifted from 
1023 at p7 to 708 at p12, while the MFI of AkaLuc population shifted 
from 746 at p7 to 388 at p12 (arbitrary units). d Cumulative doubling 
measured from passages 7 to 12 shows that cells proliferate at the 
same rate up to p11. e Flow cytometry analysis of markers that iden-
tify MSCs shows that all populations are positive for CD44, CD73, 
CD90 and CD103, and negative for CD45. f Fluorescence images of 
cells stained with phalloidin (f-actin, red) and DAPI (nuclei, blue), 
acquired at × 100 (left panel) and × 200 (right panel) magnification. 
Scale bar = 200  μm. g Area, perimeter, and circularity, as measured 
based on the phalloidin staining of at least 50 cells per replicate, show 
that MSCs retain their morphology after transduction with either of 
the reporters. Data are displayed as mean ± SD from n = 3. One-way 
ANOVA revealed no statistically significant difference between the 
three cell populations
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They were then fixed with formaldehyde (4% w/v in PBS, 
pH 7) for 20 min at room temperature (RT), washed with 
PBS, permeabilised with 0.1% (v/v) Triton X-100 in PBS 
and incubated with Alexa Fluor 594 Phalloidin (#A12381, 
ThermoFisher) [165 nM] in PBS with 1% (w/v) bovine 
serum albumin (BSA) for 1 h at RT. We used 4′,6-diamid-
ino-2-phenylindole (DAPI) [143 nM] as a counterstaining 
for the nuclei. We acquired the fluorescence images with a 
Leica DM2500 microscope coupled to a DFC350 FX cam-
era. Finally, we used ImageJ to manually delineate the cells 
using images acquired at × 100 magnification and based on 
the Phalloidin staining. The ImageJ “Analyze Particles” tool 
was used to determined cells’ area, perimeter and circularity.
Bioluminescence imaging
All bioluminescence data was obtained with an IVIS Spec-
trum instrument (Perkin Elmer) and normalised to radiance 
(photons/second/centimeter2/steradian). Where applicable, 
we used the region of interest (ROI) tool to determine the 
signal of a specific area (e.g. a single well from a well plate 
or a single animal).
To determine the light emission spectra of the reporters, 
we harvested 5 ×  103 cells and suspended them in 50 μL of 
PBS in a 0.2 mL vial. We added the substrates to the vials 
immediately before data acquisition to a final concentration 
of 160 μM for Akalumine-HCl (#6555, Bio-Techne®) and 
640 μM for D-Luciferin (E1605, Promega). Then, the light 
emitted from 500 to 840 nm was measured at 20-nm steps 
by employing the emission filters available in the system.
We measured the substrate saturation in vitro by seeding 
1.5 ×  103 cells/well into an optical bottom 96-well plate with 
black walls (#165,305, ThermoFisher). We allowed the cells 
to attach for 3 h prior to adding the substrate to the medium 
to a final concentration ranging from 2.5 μM to 5.12 mM, 
after which data was acquired immediately. We employed 
a similar protocol to calculate the flux per cell, but a range 
of cell densities was used (156 to 2 ×  104 cells/well) and the 
substrate concentration kept constant (160 μM Akalumine-
HCl or 5.12 mM D-Luciferin). Experiments were repeated 
3 times, with a technical triplicate each.
Animal experiments
We used 7–9-week-old C57 Black 6 (C57BL/6) albino 
female mice for all animal experiments. Mice were obtained 
from a colony managed by the Biomedical Services Unit 
at the University of Liverpool (UK) which had been estab-
lished from the B6N-Tyrc−Brd/BrdCrCrl strain originally 
purchased from Charles River (Italy). Mice were housed in 
individually ventilated cages (IVCs) under a 12-h light/dark 
cycle and provided with standard food and water ad libi-
tum. All animal procedures were performed under a licence 
granted under the Animals (Scientific Procedures) Act 1986 
and were approved by the University of Liverpool Animal 
Ethics Committee.
For cell administration, the mice were anaesthetised with 
isoflurane and intravenously (IV) injected with 2.5 ×  105 UC-
MSCs suspended in 100 μL of PBS. Then, under the same 
anaesthesia session, the animals received a subcutaneous 
(SC) or intraperitoneal (IP) injection of the substrate prior 
to imaging with the IVIS. All imaging procedures in subse-
quent days were carried out under anaesthesia, including the 
administration of the substrates. For kinetic analysis of the 
signal, BLI data was acquired continuously from substrate 
administration for up to 30 min.
The AkaLuc-HCl substrate was used at a fixed dose of 
100 μL of a 30 mM stock, which was previously reported to 
give a maximum signal in vivo [15]. D-Luciferin was used 
at either 10 μL/g of a 47 mM stock solution (“low dose”) 
or 20 μL/g of a 144.5 mM stock solution (“high dose”). To 
keep the administered volumes constant between groups that 
received D-Luciferin, animals that received the “low dose” 
were injected with an additional 10 μL/g of PBS, irrespec-
tive of the administration route. Quantification of BLI signal 
from animals was obtained from a region of interest covering 
the whole body of an individual mouse. More information 
about the experimental conditions for each animal experi-
ment can be found in Supplementary Tables 1–3. Our data is 
reported in line with the ARRIVE guidelines [20].
Statistical analysis
All values in graphs are represented as mean ± standard 
deviation. The statistical analysis was performed using the 
GraphPad software. The type of statistical test and the num-
ber of replicates included in the analyses are indicated in 
the figure legends.
Results
Impact of reporter gene expression on MSC 
properties
We produced UC-MSCs expressing FLuc or AkaLuc by 
lentiviral transduction with vectors sharing the same back-
bone and encoding for either of the reporters (Fig. 1a). 
Figure 1b shows phase contrast images of confluent con-
trol,  AkaLuc+ and  FLuc+ MSCs, and the respective green 
fluorescence images, showing ZsGreen expression by all 
cells. This was also confirmed by flow cytometry, with 
both cell populations having close mean green fluores-
cence intensities, indicating similar levels of expression 
of the transgenes (Fig. 1c). Cumulative doubling of the 
genetically modified cells from p7 to p10 (Fig. 1d) was 
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the same as the untransduced control, suggesting that pro-
liferation rate was not affected by insertion of the report-
ers. After this passage, all populations appear to display a 
slight decrease in doublings, which is more pronounced for 
the transduced cells (Fig. 1d). Flow cytometry analyses of 
ZsGreen expression at p7 and p12 show that  FLuc+ cells 
are still all positive at p12, while there was a little reduc-
tion in the level of expression in  AkaLuc+ cells (Fig. 1c). 
Expression of common mesenchymal markers was simi-
lar in all three populations, with a good overlap of the 
flow cytometry data (Fig. 1e), revealing that the marker 
expression was not altered by either of the reporter genes 
and that all cells were negative for CD45 and positive for 
CD44, CD73, CD90, and CD105 (Fig. 1e). Morphological 
analysis of the three cell populations showed no statisti-
cally significant difference in the area, perimeter, or cir-
cularity of MSCs, regardless of the genetic modification 
(Fig. 1f and g).
Characterisation of the reporter systems in vitro
Imaging of MSCs with increasing concentrations of 
Akalumine-HCl or D-Luciferin revealed that  FLuc+ cells 
display significant light emission with either of the sub-
strates, while  AkaLuc+ cells only emit significant light 
when exposed to Akalumine-HCl (Fig. 2a). Quantification 
of the signal in individual wells shows that both  FLuc+ and 
 AkaLuc+ cells in the presence of Akalumine-HCl display 
Fig. 2  The AkaLuc and FLuc reporters saturate at different substrate 
concentrations in  vitro. AkaLuc and FLuc expressing MSCs were 
seeded at a density of 1.5 ×  103 cells/well and treated with increas-
ing concentrations of Akalumine-HCl or D-Luciferin (2.5  μM to 
5.12 mM). a Representative images of a well plate immediately after 
the substrate addition to the cells. b, c Light output (flux) as a func-
tion of substrate concentration, where b shows the signal obtained 
from 2.5  μM to 5.12  mM and c from 2.5  μM to 640  μM. Data are 
displayed as mean ± SD from n = 3. Acquisition parameters: no emis-
sion filters, 13.3 cm field of view (FOV), f-stop of 1, binning of 8 and 
10 s of exposure
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maximum flux at very low substrate concentrations, while 
FLuc cells incubated with D-Luciferin display a slow 
increase in signal up to 5.12 mM (Fig. 2b, c). Both cell 
populations are saturated and reach a plateau at approxi-
mately 20 μM for Akalumine-HCl (Fig. 2c, Supplemen-
tary Fig. 2a). At this concentration, the light emitted by 
 AkaLuc+ cells is 11.8- and sixfold greater than the signal 
emitted by  FLuc+ cells with D-Luciferin or Akalumine-
HCl, respectively (Fig. 2c). Interestingly, the signal from 
AkaLuc and FLuc cells exposed to Akalumine-HCl at 
concentrations higher than 640 μM drops slightly (Fig. 2b, 
Supplementary Fig. 2b). Even when increasing the dose of 
the substrates to up to 5.12 mM, the signal generated by 
 FLuc+ cells in the presence of D-Luciferin does not fully 
saturate, although the slope of the curve starts to level out. 
At this concentration, the signal produced by  FLuc+ cells 
is fourfold greater than the signal generated by  AkaLuc+ 
cells saturated with Akalumine-HCl (Fig. 2b).
Measurements of the spectral properties of the reporters 
show that  AkaLuc+ cells display a peak at 650 nm when 
Fig. 3  Emission spectra and 
light output as a function of 
cell density for the AkaLuc and 
FLuc reporter systems. a Emis-
sion spectrum for each enzyme/
substrate pair, as measured by 
acquiring the signal emitted 
from 500 to 840 nm at 20 nm 
steps. Data is normalised to the 
peak value of each condition. 
The AkaLuc/Akalumine-HCl 
system displays a peak at 
650 nm, whereas FLuc cells 
display a peak at 600 nm in 
the presence of D-Luciferin 
and 670 nm in the presence of 
Akalumine-HCl. Haemoglobin 
(Hb) absorption (average of 
values of oxy-Hb and deoxy-
Hb) is plotted in grey (unit 
of measure: molar extinction 
coefficient as shown on the right 
axis). b, c AkaLuc and FLuc 
expressing MSCs were seeded 
at a density of 156 to 2 ×  104 
cells/well and treated with a 
saturating concentration of the 
substrates (160 μM Akalumine-
HCl or 5.12 mM D-Luciferin). 
AkaLuc expressing cells were 
treated with Akalumine-HCl 
only, whereas FLuc expressing 
cells were treated with AkaLuc-
HCl or D-Luciferin. The signal 
was acquired using a 660 nm 
filter. b Representative images 
of a well plate immediately after 
the substrate addition. c Light 
output (flux) as a function of 
cell concentration, with linear 
regression curves. The slope 
of each curve represents the 
flux/cell and is shown in the 
legend. Data are displayed as 
mean ± SD from n = 3. Acquisi-
tion parameters: 13.3 cm FOV, 
f-stop of 1, binning of 8 and 
10 s of exposure
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supplied with Akalumine-HCl.  FLuc+ cells, on the other 
hand, display a peak at 670 nm when supplied with Akalu-
mine-HCl and at 600 nm when supplied with D-Luciferin 
(Fig. 3a). While a significant portion of the light emitted by 
the FLuc/D-Luciferin system overlaps with the absorption 
of haemoglobin, almost all the light emitted by the AkaLuc/
Akalumine-HCl does not (Fig. 3a).
To obtain the flux per cell, we plated MSCs at various 
densities from 156 to 2 ×  104 cells/well and we subsequently 
imaged them in the presence of Akalumine-HCl or D-Lucif-
erin at a final concentration of 160 μM and 5.12 mM, respec-
tively. This corresponds to concentrations well above the 
saturation for AkaLuc/Akalumine-HCl and the highest dose 
of D-Luciferin used in this study, which provided the strong-
est signal with FLuc. We measured the light output with a 
660-nm filter (19.57 nm bandwidth), which is physiologi-
cally relevant as it is in the near-infrared optical imaging 
window and also matches the emission peak of the AkaLuc/
Akalumine-HCl system (650 nm). Both reporter systems 
display considerable light emission (Fig. 3b) and a linear 
regression of the signal measured in each well demonstrates 
that the flux of  AkaLuc+ cells (1346 p/s/cell) is nearly six-
fold higher than  FLuc+ cells with Akalumine-HCl (218.5 
p/s/cell), but only slightly stronger than  FLuc+ cells with 
D-Luciferin (1139 p/s/cell) (Fig. 3c). If no light emission 
filter is applied and data is acquired for the whole spectrum, 
the light output from FLuc/D-Luciferin significantly out-
performs AkaLuc/Akalumine-HCl (Supplementary Fig. 3).
Light emission kinetics in vivo
To determine the kinetic of the BLI signal in vivo, mice 
that received 250 ×  103  FLuc+ or  AkaLuc+ MSCs were 
imaged every minute for 30 min after administration of 
the substrates. From this point on, we compare only the 
FLuc/D-Luciferin and AkaLuc/Akalumine-HCl systems 
and we investigate two doses of D-Luciferin: the commonly 
reported 0.47 mmol/kg and a higher dose of 2.89 mmol/kg. 
We used Akalumine-HCl at the fixed dose of 100 μL of a 
30-mM solution, which has previously been reported to be 
associated with maximum signal in vivo [15]. Representa-
tive bioluminescence images of mice acquired 5, 18, and 
30 min post-SC or IP injection of the substrates are shown in 
Fig. 4a, c and are displayed in the same colour scale to allow 
a direct comparison of the data. A signal is detected from 
all mice irrespective of the substrate administration route, 
which shows cells lodging in the lungs (Fig. 4a, c). In the SC 
route, the signal reaches a maximum between 16 and 28 min 
after the administration of the substrate (Fig. 4b). The signal 
from  FLuc+ cells stays stable for about 7 min before starting 
to decrease. The light emitted by  AkaLuc+ cells, on the other 
hand, seems to remain stable after reaching its maximum 
(Fig. 4b). For both reporters, a window exists at 20 min post 
administration of the substrate where over 96% of maximum 
light output is achieved, which we have used for subsequent 
experiments. Data acquisition 24 h post cell administration 
confirmed this time course (Supplementary Fig. 4). In the 
IP route, the FLuc system displays a time course that resem-
bles that obtained following SC administration, with a rapid 
increase of the signal in the first minutes post administration, 
followed by a slower increase up to minute 30 (Fig. 4d). By 
contrast, the AkaLuc system resulted in maximum signal 
intensity shortly after the injection of the substrate (min 5, 
Fig. 4b) followed by a rapid drop in the signal. Similar anal-
ysis performed on day 1, day 3, and day 7 shows that while 
the FLuc system displays the same kinetics at all time points, 
the AkaLuc system changed from day 3, with an increase in 
flux over time (Supplementary Fig. 5).
Reporter gene sensitivity and specificity in vivo
To assess the sensitivity of the two reporter genes in vivo, 
we measured the signal from the MSCs for up 7 days post 
administration into mice. Based on the data presented in 
the previous section, all measurements are at 20 min post 
administration of the substrate except for Akalumine-HCl 
administered IP, where measurements are at minute 5 for day 
0 and at minute 3 for days 1, 3, and 7. In all conditions, there 
is a strong signal in the lungs on the administration day, 
which drops by day 1 and is mostly lost by day 3 (Fig. 5a 
and c). The same data at a lower colour scale are shown in 
Supplementary Fig. 6, where it is still possible to detect a 
signal on day 3 in mice injected with  FLuc+ cells and a high 
dose of D-Luciferin and in mice injected with  AkaLuc+ cells 
and Akalumine-HCl.
The quantification of the signal revealed that when the 
substrates are administered SC, the signal drops substan-
tially from day 0 to 1 in all conditions (18-fold for AkaLuc/
Akalumine-HCl, 13-fold for FLuc/D-Luciferin low dose 
and ninefold for FLuc/D-Luciferin high dose) and drops 
again from day 1 to 3 (sevenfold for AkaLuc/Akalumine-
HCl, 13-fold for FLuc/D-luciferin low dose and 22-fold for 
FLuc/D-luciferin high dose) (Fig. 5b). With the IP route, 
the signal drops from day 0 to 1 in all conditions (17-fold 
for AkaLuc/Akalumine-HCl, 21-fold for FLuc/D-Luciferin 
low dose and 12-fold for FLuc/D-Luciferin high dose) and 
again from day 1 to 3 (18-fold for AkaLuc/Akalumine-HCl, 
sevenfold for FLuc/D-Luciferin low dose and 22-fold for 
FLuc/D-luciferin high dose) (Fig. 5d). This drop in signal 
over time is expected given that it is widely reported that 
most MSCs die shortly after IV administration [3, 21, 22].
With the SC route, mice injected with  FLuc+ cells and 
the high dose of D-luciferin displayed the highest signal out-
put, with the average light emission being 4.5-fold higher 
than the signal obtained with FLuc cells with low dose of 
D-Luciferin, and 3.2-fold higher than the signal acquired 
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with AkaLuc cells. The signal emitted by the FLuc system 
at a low dose of D-luciferin is comparable, and not statisti-
cally different to the signal emitted by the AkaLuc system.
With substrate administration IP, the AkaLuc system 
displays the highest signal output, with the average light 
emission being 1.6-fold higher than the signal obtained with 
 FLuc+ cells with a high dose of D-Luciferin, and 6.1-fold 
higher than  FLuc+ cells with a low dose of D-Luciferin 
(Fig. 5d). However, visualisation of the data at a lower 
colour scale reveals that mice receiving Akalumine-HCl 
IP displayed a signal away from the lungs on days 3 and 
7 (Supplementary Fig. 6). At 20 min post administration 
of the substrate, the AkaLuc signal was even stronger and 
originated from a region corresponding to the liver. This 
was absent in animals receiving D-Luciferin (Supplemen-
tary Fig. 7).
To investigate the origin of this signal, we injected naïve 
mice that did not receive any cells, with the substrates IP. 
While mice that received luciferin displayed no biolumi-
nescence, those injected with Akalumine-HCl presented a 
signal coming from the liver which is detectable both in 
dorsal and ventral positions (Fig. 6a). Quantitative analysis 
of the data reveals a statistically significant increase in the 
total flux emitted by Akalumine-HCl alone, both ventrally 
and dorsally, when compared to D-Luciferin that displays 
no specific signal (Fig. 6b), which is consistent with a pre-
viously observed hepatic background [23]. Importantly, the 
signal detected in the dorsal position following IP adminis-
tration of Akalumine-HCl in naïve mice is comparable to the 
signal detected in mice injected with AkaLuc cells 3 days 
post administration of the cells (Fig. 6c).
Finally, we identified a reaction in the skin of mice 
injected SC with Akalumine-HCl. Analysis of the carcasses 
of mice that were culled on day 10 post administration of the 
cells, after they had undergone 4 imaging sessions, revealed 
that animals that had received Akalumine-HCl SC showed 
lesions that were noticeable when the skin was shaved. 
These lesions corresponded to the sites of the SC injections 
and displayed different grades of severity (Supplementary 
Fig. 8a). No changes to the appearance of the skin of mice 
treated with D-Luciferin even when using the high dose 
(Supplementary Fig. 8b) were seen. No abnormalities were 
identified in the peritoneum of mice that received Akalu-
mine-HCl IP.
Discussion
The purpose of this study was to determine whether the Aka-
BLI system truly offers a gain in sensitivity when compared 
to the well-established FLuc/Luciferin system, with a focus 
on its use to track the biodistribution of MSCs. Our first 
goal was to ensure that the expression of the transgene was 
equivalent between the cell populations we compared. We 
achieved that by lentiviral transduction using the same MOI 
and vector, with the only change being the gene encoding for 
the bioluminescence enzyme, and flow cytometry selection 
based on equivalent fluorescence intensity of the ZsGreen 
marker. This is important because the previously reported 
study on the use of AkaBLI not only involved transfection, 
a method which only generates transient expression, but 
also the selection of “highly fluorescent transfectants” [15], 
meaning that different populations of cells could have dif-
fering levels of the transgenes. As measured indirectly by 
ZsGreen fluorescence, both  AkaLuc+ and  FLuc+ MSCs in 
our study had a comparable and stable expression of the 
inserts.
Transduction with the vectors did not result in any 
changes in marker expression, proliferation, or morphology 
of UC-MSCs, providing evidence that the genetic modifica-
tion with either luciferase is likely safe. The functionality of 
the reporters was verified by their specificity to the correct 
substrates and the emission spectra, with the AkaLuc system 
displaying a distinct shift to 650 nm, as opposed to the FLuc 
system which has a maximum emission at 600 nm.
Substrate saturation in vitro, as measured by the concen-
tration required to obtain maximum light output, differed 
between the two populations. Whereas  AkaLuc+ cells resulted 
in a quick saturation of the signal at 20 μM of Akalumine-
HCl,  FLuc+ cells did not fully saturate with luciferin concen-
trations of up to 5.12 mM. Interestingly, previous comparisons 
of these systems employed relatively low concentrations of 
substrates. For example, Kuchimaru and colleagues pre-
sented light output data with substrate concentrations of up 
to 250 μM [16], whereas Iwano and colleagues used substrates 
at up to 500 μM [15]. These studies suggested that AkaLuc 
performs better at low substrate concentrations, which is in 
agreement with our data and studies that have shown a low 
Km for this and other engineered substrates [24]. However, 
Fig. 4  FLuc and AkaLuc systems display similar signal kinet-
ics in  vivo when the substrate is administered subcutaneously, but 
not when administered intraperitonially. MSCs (2.5 ×  105) express-
ing either AkaLuc or FLuc were administered via the tail vein. The 
mice then received the substrates either subcutaneously or intraperi-
tonially, under the same anaesthesia session, after which they were 
imaged every minute for 30 min (kinetic analysis). a Representative 
images of the mice 5, 18 and 30 min post -SC administration of the 
substrates (radiance scale from 1 ×  105 to 2 ×  106 p/s/cm2/sr). b Light 
output (flux) as a function of time, from minute 4 to minute 31. Data 
are displayed as mean ± SD from n = 3. c Representative images of 
the mice 5, 18, and 30  min post-IP administration of the substrate 
(radiance scale from 1 ×  105 to 2 ×  106 p/s/cm2/sr). d Light output 
(flux) as a function of time, from minute 5 to 31. Data are displayed 
as mean ± SD from n = 4. Low-dose D-Luciferin = 0.47  mmol/kg; 
high dose D-Luciferin = 2.89 mmol/kg; Akalumine HCl = 100 μL of 
30 mM solution. Acquisition parameters: no emission filter, 22.8 cm 
FOV, f-stop of 1, binning of 8 and a maximum exposure of 45 s for 
each time point
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our observations demonstrate that FLuc is more sensitive 
when high concentrations of the D-Luciferin substrate are 
employed. Because D-luciferin substrate has relatively high 
aqueous solubility and a low cost, we propose that this places 
D-Luciferin substrate at an advantage in BLI applications 
when compared to Akalumine-HCl. Even when the light out-
put per cell was measured with a 660-nm filter, which results 
in a bias towards the AkaLuc system, our data suggest that the 
two systems are quite similar in terms of light emitted per cell, 
with 1346 p/s/cell and 1139 p/s/cell for  AkaLuc+ and  FLuc+ 
cells, respectively.
A critical aspect of our study was to determine whether 
the in vitro data is translated in vivo. This is important 
because the light output is dependent, among other factors, 
on the bioavailability of the substrate in the model organism. 
The standard dose of D-Luciferin used for in vivo BLI is 
0.47 mmol/kg body weight [7, 12, 25, 26]. However, it has 
been shown that higher doses are associated with stronger 
FLuc signal in vivo [7]. Because of that, we increased the 
dose of D-Luciferin to 2.89 mmol/kg body weight (approxi-
mately sixfold). We achieved that by preparing stock solu-
tions of the substrate at its solubility limit (144.5 mM), fol-
lowed by increasing the injection volume to up to 20 mL/kg 
body weight, which is recognised as the maximum volume 
permitted under animal welfare guidance [27]. Akalumine-
HCl was used at the previously reported optimal dose [15]. 
Both systems were able to show that MSCs are delivered to 
the lungs after IV administration, regardless of the substrate 
administration route.
However, there were clear differences between the signal 
intensity of the AkaLuc and FLuc systems depending on 
the route of substrate administration: in the SC route, the sig-
nal intensity of  AkaLuc+ cells was not stronger than  FLuc+ 
when standard substrate doses were used (100 μL of 30 mM 
Akalumine-HCl and 0.47 mmol/kg body weight D-Lucif-
erin). By increasing the D-Luciferin dose to 2.89 mmol/kg 
body weight, the light output obtained with the FLuc sys-
tem increased significantly by at least threefold. Both BLI 
systems displayed a similar substrate biodistribution kinet-
ics, with the signal reaching a plateau that allows consistent 
acquisition of data.
In contrast, when the substrates were administered IP, the 
signal intensity of  AkaLuc+ cells was stronger than  FLuc+ 
cells, irrespective of whether a high or low dose of luciferin 
was administered. The  AkaLuc+ cells displayed a kinetics char-
acterised by a peak immediately after administration of the 
substrate. This means that for maximum signal intensity, data 
acquisition needs to proceed quickly after the administration of 
the substrate. Moreover, due to the rapid decay in signal, the 
experimental design needs to take into consideration a need for 
consistent timing between injection of the substrate and data 
acquisition for each animal. Of note, the kinetics in our study 
is very different to Iwano’s study [15] involving intracranial 
administration of cells, where the signal after IP administration 
of substrate peaked at approximately 15 min. This discrepancy 
raises further questions on the reliability of the system for imag-
ing cells that might be present in different organs. Furthermore, 
it is well known that IP administration of BLI substrates can 
lead to unreliable data due to injection failure rate and irregular 
distribution of the substrate [28].
In all conditions, regardless of the route of administra-
tion of the substrates, the signal dropped from day 0 to 1 
and almost disappeared by day 3. This result is consistent 
with cell death and widely reported in the literature [3, 21, 
22]. However, it is important to emphasise that only FLuc 
in combination with a high dose of D-Luciferin allowed us 
to unambiguously ascertain that there were still viable cells 
in the lungs on day 3 post administration.
An additional drawback observed with the AkaBLI system 
was the existence of an unspecific liver signal when the sub-
strate was injected IP, found even in naïve mice. Although we 
are not the first to report the accumulation of Akalumine-HCl 
in the liver [29], or its unspecific bioluminescence [23], what 
is striking is that on day 3 post cell administration, quanti-
fication of the signal shows that the unspecific signal from 
Akalumine-HCl is actually as strong as the MSC-specific 
signal from FLuc combined with D-Luciferin, highlighting 
the potential for serious inaccuracies.
Akalumine-HCl has been reported to be more cytotoxic than 
most other substrates in vitro [6, 30] and to our knowledge, tox-
icity has not been previously reported in animals. However, we 
observed the formation of lesions in sites of SC injection of 
Akalumine-HCl, with different degrees of severity. We have not 
investigated the nature of these lesions; however, it is clear that 
Fig. 5  The AkaLuc and the FLuc reporter systems display a differ-
ent sensitivity over time following SC and IP administration of the 
substrates. UC-MSCs (2.5 ×  105) expressing either the FLuc or the 
AkaLuc transgene were administered via the tail vein and the mice 
were imaged at day 0 (administration day) and 1, 3, or 7  days post 
cell administration. D-Luciferin (low or high dose) or Akalumine-
HCl were used as substrates and administered either SC or IP. a Rep-
resentative images of the mice as acquired 20 min post-SC adminis-
tration of the substrates (radiance scale from 1 ×  105 to 2 ×  106 p/s/
cm2/sr). b Light output (flux) as a function of time (day). Data are 
displayed as mean ± SD from n = 3 (D-Luciferin low dose), n = 7 
(D-Luciferin high dose and Akalumine-HCl). The FLuc reporter in 
combination with a high dose of D-luciferin yields a stronger signal 
in all days. c Representative images of the mice acquired at peak sig-
nal of each condition (20 min for D-Luciferin and 5 min (for D0) or 
4 min (for D1, 3, and 7) for Akalumine-HCl) following IP adminis-
tration of the substrates (radiance scale from 1 ×  105 to 2 ×  106 p/s/
cm2/sr). d Light output (flux) as a function of time (days). Data are 
displayed as mean ± SD from n = 4. Statistical analysis was performed 
using a two-way ANOVA and Tukey’s multiple comparison post hoc 
test. *p < 0.05; **p < 0.01., ***p < 0.001. Acquisition parameters: no 
emission filter, 22.8 cm FOV, f-stop of 1 and a binning of 8. FLuc/D-
Luciferin exposure time: 45 s for D0 and D1, and 180 s for D3 and 
D7. AkaLuc/Akalumine-HCl exposure time: 45  s for D0 and 180  s 
for D1, 3, and 7
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it leads to an abnormal reaction in the animal’s skin. A recent 
study has suggested that the pH of Akalumine-HCl stock solu-
tion is 2.25 [31], which could possibly explain this reaction. 
Administration of substrate IP has not revealed any abnormali-
ties; this could be because the effects are less severe than SC, 
because the less targeted nature of IP delivery makes it more 
difficult to identify the specific injection area, or because SC 
administration is associated with a higher local concentration 
of the substrate compared to IP.
In conclusion, our study emphasises the superiority of 
the FLuc/D-Luciferin system for tracking cells in vivo. In 
particular, we found that the FLuc system has a better per-
formance in terms of (i) stronger signal with SC administra-
tion of substrate, which has no bias towards organs of the 
torso; (ii) signal kinetics, exhibiting a plateau whether the 
substrate is administered SC or IP, offering a uniform data 
acquisition window; and (iii) safety, with a non-toxic sub-
strate that is specific to the enzyme of interest. AkaBLI with 
IP administration of the substrate might lead to a stronger 
signal in organs in or close to the peritoneum immediately 
after substrate administration, but at the expense of the data 
being potentially inconsistent due to its other limitations. We 
therefore urge caution when interpreting the data obtained 
with AkaBLI, suggest that FLuc with a high dose of lucif-
erase ought to be considered as an option for studies that 
require high sensitivity, and emphasise the need for further 
systematic comparative studies to determine the perfor-
mance of more recently developed substrates such as Sem-
Pai, iLH2 and NIRLuc2 [24].
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Fig. 6  In the absence of cells, Akalumine-HCl generates a non-spe-
cific signal from the liver when administered IP. High-dose D-Lucif-
erin or Akalumine-HCl was injected IP in vivo. The mice were then 
imaged in dorsal (23  min post substrate administration) and ventral 
(20  min post administration) positions, with no emission filter, a 
22.8 field of view, a f-stop of 1, a binning of 8 and an exposure time 
of 180  s. a Representative images of the mice following substrate 
administration (radiance scale from 1 ×  104 to 1 ×  105 p/s/cm2/sr). b 
Quantification of the non-specific signal detected in the liver region 
of the mice injected with Akalumine-HCl IP, analysed both in ven-
tral and dorsal position, compared with the signal coming from the 
liver region of mice injected with high dose D-Luciferin IP. Data are 
displayed as mean ± SD from n = 3. Statistical analysis performed 
using a one-way ANOVA and Tukey’s multiple comparison post hoc 
test. ***p < 0.001 post substrate administration. c Comparison of the 
signal detected in the liver of mice injected with Akalumine-HCl, 
three days post administration of 2.5 ×  105 AkaLuc expressing cells 
IV (n = 4) vs. the non-specific luminescence from naive mice that 
received Akalumine-HCl alone (n = 3), 20  min. There is no statisti-
cally significant difference between the two groups (unpaired t-test). 
Data are displayed as mean ± SD
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